Actively Recruiting

Phase 4
Age: 18Years - 65Years
All Genders
NCT06778213

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Led by Wroclaw Medical University · Updated on 2025-01-28

67

Participants Needed

1

Research Sites

108 weeks

Total Duration

On this page

Sponsors

W

Wroclaw Medical University

Lead Sponsor

A

ALL-MED Medical Research Institute, Wroclaw, Poland

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main objective of the study is to measure and correlate clinical parameters suitable for the assessment of allergen immunotherapy (AIT) with an aluminum hydroxide-adsorbed preparation of house dust mite (Dermatophagoides pteronyssinus/ Dermatophagoides farinae) allergens in adults with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic bronchial asthma caused by house dust mite (HDM) allergens. The assessment of clinical responses will be evaluated following an allergen challenge in allergen exposure chamber (AEC) before and during the course of AIT. Patients' response to therapy will be evaluated as well as in the AEC and by patient's personal environment (Diary).

CONDITIONS

Official Title

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent given before any trial activities
  • Male or female outpatient aged 18 to 65 years
  • Moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite allergens confirmed by positive skin prick test and specific IgE
  • Symptoms present for at least 2 years including October to February or year-round
  • Persistent moderate to severe rhinitis symptoms for at least 4 consecutive weeks and 4 days per week, impacting daily activities or sleep
  • Regular need for anti-symptomatic medication
  • Previous anti-allergic medication use for at least 2 seasons
  • No asthma diagnosis or well-controlled asthma according to guidelines at trial entry
Not Eligible

You will not qualify if you...

  • Unable to understand or comply with trial requirements
  • Participation in another clinical trial within 30 days before consent
  • Low adherence expected or unable to understand trial instructions
  • Involved in trial planning or dependent on investigator
  • Previously randomized in this trial
  • Mentally disabled or institutionalized
  • Pregnant, breastfeeding, or unwilling to use effective contraception if female with childbearing potential
  • History of anaphylaxis after allergen immunotherapy injection
  • Currently receiving or received allergen immunotherapy for house dust mite or unknown allergens within 5 years
  • Symptoms from other perennial or seasonal allergens affecting assessment period except cat or dog allergens without direct contact
  • Chronic or non-allergic respiratory symptoms
  • Chronic rhinitis symptoms lasting 20 years or more
  • Lung function below 70% predicted despite asthma treatment
  • Uncontrolled or partly controlled asthma
  • Asthma exacerbation in past 6 months requiring systemic steroids or hospitalization
  • Severe acute or chronic diseases including infections, autoimmune or inflammatory diseases
  • Severe psychiatric disorders or substance abuse
  • Recurrent seizures or irreversible lung damage
  • Laboratory abnormalities beyond normal reference ranges
  • Use of beta-blockers or ACE inhibitors
  • Contraindications for adrenaline use
  • Use of anti-IgE, anti-IL4/IL13 antibodies, or other immunomodulatory drugs
  • Long-term treatment with tranquilizers or psychoactive drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

ALL-MED Medical Research Institute

Wroclaw, DL, Poland, 53-201

Actively Recruiting

Loading map...

Research Team

M

Marek M Jutel, prof.

CONTACT

M

Magdalena E Zemelka-Wiacek, Dr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here